Premium
Age‐related EBV‐associated B‐cell lymphoproliferative disorders and other EBV + lymphoproliferative diseases: New insights into immune escape and immunodeficiency through staining with anti‐PD‐L1 antibody clone SP142
Author(s) -
Sakakibara Ayako,
Kohno Kei,
Ishikawa Eri,
Suzuki Yuka,
Shimada Satoko,
Eladl Ahmed E.,
Elsayed Ahmed A.,
Daroontum Teerada,
Satou Akira,
Takahara Taishi,
Ohashi Akiko,
Takahashi Emiko,
Kato Seiichi,
Nakamura Shigeo,
Asano Naoko
Publication year - 2020
Publication title -
pathology international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 74
eISSN - 1440-1827
pISSN - 1320-5463
DOI - 10.1111/pin.12946
Subject(s) - lymphoproliferative disorders , lymphoma , immunodeficiency , immunology , epstein–barr virus , immune system , pathology , primary effusion lymphoma , biology , antibody , medicine , virus
Epstein–Barr virus (EBV) is prevalent among healthy individuals, and is implicated in numerous reactive and neoplastic processes in the immune system. The authors originally identified a series of senile or age‐related EBV‐associated B‐cell lymphoproliferative disorders (LPD) bearing a resemblance to immunodeficiency‐associated ones. These LPDs may be associated with immune senescence and are now incorporated into the revised 4th edition of 2017 WHO lymphoma classification as EBV‐positive (EBV+) diffuse large B‐cell lymphoma (DLBCL), not otherwise specified (NOS). These EBV+ B‐cells often have a Hodgkin/Reed‐Sternberg (HRS)‐like appearance and are shared beyond the diagnostic categories of mature B‐cell neoplasms, mature T‐cell neoplasms, classic Hodgkin lymphoma, and immunodeficiency‐associated LPD. In addition, peculiar new diseases, such as EBV+ mucocutaneous ulcer and EBV+ DLBCL affecting the young, were recognized. On the other hand, lymphoma classification is now evolving in accord with deeper understanding of the biology of programmed death ligand 1 (PD‐L1). Assessing PD‐L1 positivity by staining with the anti‐PD‐L1 monoclonal antibody SP142 provides new insight by discriminating between immune evasion and senescence or immunodeficiency. The aim of the present review is to briefly summarize the diagnostic use of immunostaining with SP142 in malignant lymphomas and/or LPDs that feature tumor and nonmalignant large B‐cells harboring EBV.